Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

NCT05990920 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Pathologically Confirmed Cancer Refractory to Conventional Therapy
Refractory Cancer
Metastatic Cancer
Recurrent Cancer
Solid Tumor, Adult
Solid Tumor
Advanced Cancer
Advanced Solid Tumor

Interventions

BIOLOGICAL: SNK02

Sponsor

NKGen Biotech, Inc.